A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 1626 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Study Start Date: September 25, 2009
Primary Completion Date: October 1, 2011
Study Completion Date: October 31, 2011
Arm:
- Experimental: FF/GW642444 Inhalation Powder 100/25 mcg QD
- Experimental: FF/GW642444 Inhalation Powder 200/25 mcg QD
- Experimental: FF/GW642444 Inhalation Powder 50mcg/25mcg QD
- Experimental: GW642444 25mcg QD
| Category | Value |
|---|---|
| Date last updated at source | 2017-11-09 |
| Study type(s) | Interventional |
| Expected enrolment | 1626 |
| Study start date | 2009-09-25 |
| Estimated primary completion date | 2011-10-01 |